
|Videos|July 12, 2016
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Role of DPR in Colorectal Cancer
Author(s)Volker Heinemann, MD, PhD
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.
Advertisement
Articles in this issue
over 9 years ago
Overview of the Lume 1 and 2 Trialsover 9 years ago
Impact of HER2 Amplification in Colorectal Cancerover 9 years ago
Novel Immunotherapy Combinations on Horizon for mCRCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5







































